Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications

Spampinato, Simona Federica; Sortino, Maria Angela; Salomone, Salvatore

doi:10.1016/bs.apha.2022.02.001

Cited by 4 publications

(3 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 50) S1P binds and activates five receptor subtypes: S1P1, S1P2, S1P3, S1P4, S1P5, widely expressed in different organs, tissues, and cells. 51) The S1P1 receptor was found in the heart, the S1P3 receptor was detected in vessels. 51) Inhibition of sphingosine kinase by dimethylsphingosine eliminates the cardioprotective effect of cangrelor.…”

Section: The P2y 12 Receptor Antagonistsmentioning

confidence: 99%

“… 51) The S1P1 receptor was found in the heart, the S1P3 receptor was detected in vessels. 51) Inhibition of sphingosine kinase by dimethylsphingosine eliminates the cardioprotective effect of cangrelor. 41) Thus, the protective mechanism of cangrelor seems to be associated with enhancement of S1P synthesis and its release from platelets ( Figure 3 ).…”

Section: The P2y 12 Receptor Antagonistsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists

et al. 2022

View full text Add to dashboard Cite

Author's summary High mortality among people with acute myocardial infarction is one of the most urgent problems of modern cardiology. And in recent years, much attention has been paid to the search for pharmacological approaches to prevent heart damage. In this review, we tried to analyze data on the effect of P2Y 12 receptor antagonists on the ischemia/reperfusion tolerance of the heart.

show abstract

Section: The P2y 12 Receptor Antagonistsmentioning

confidence: 99%

Section: The P2y 12 Receptor Antagonistsmentioning

confidence: 99%

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One of the possible interventions in the treatment of MS is the modulation of sphingosine 1 phosphate (S1P) receptors. S1P is a bioactive sphingolipid that modulates several physiological and pathological processes by acting on five receptors (S1P1-S1P5), broadly expressed in several tissues and districts of the body [ 18 ]. Acting as a functional S1P1 antagonist, fingolimod, the first-in-class S1P1/S1P5 modulator, prevents leukocytes’ egress from the lymph nodes [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Microglia Contributes to BAF-312 Effects on Blood–Brain Barrier Stability

et al. 2022

Self Cite

View full text Add to dashboard Cite

Microglia, together with astrocytes and pericytes, cooperate to ensure blood–brain barrier (BBB) stability, modulating endothelial responses to inflammatory insults. Agonists of the sphingosine 1 phosphate (S1P) receptors, such as siponimod (BAF-312), are important pharmacological tools in multiple sclerosis and other inflammatory diseases. Modulation of S1P receptors may result in a reduced inflammatory response and increased BBB stability. An in vitro BBB model was reproduced using human-derived endothelial cells, astrocytes and microglia. Co-cultures were exposed to inflammatory cytokines (TNFα, 10 UI and IFNγ, 5 UI) in the presence of BAF-312 (100 nM), and the BBB properties and microglia role were evaluated. The drug facilitated microglial migration towards endothelial/astrocyte co-cultures, involving the activity of the metalloprotease 2 (MMP2). Microglia actively cooperated with astrocytes in the maintenance of endothelial barrier stability: in the triple co-culture, selective treatment of microglial cells with BAF-312 significantly prevented cytokines’ effects on the endothelial barrier. In conclusion, BAF-312, modulating S1P receptors in microglia, may contribute to the reinforcement of the endothelial barrier at the BBB, suggesting an additional effect of the drug in the treatment of multiple sclerosis.

show abstract

Advances in research on potential inhibitors of multiple myeloma

Tang,

Huang,

Luo

et al. 2023

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications

Cited by 4 publications

References 205 publications

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists

Microglia Contributes to BAF-312 Effects on Blood–Brain Barrier Stability

Advances in research on potential inhibitors of multiple myeloma

Contact Info

Product

Resources

About

Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications

Cited by 4 publications

References 205 publications

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y12 Receptor Antagonists

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y12 Receptor Antagonists

Microglia Contributes to BAF-312 Effects on Blood–Brain Barrier Stability

Advances in research on potential inhibitors of multiple myeloma

Contact Info

Product

Resources

About

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y₁₂ Receptor Antagonists